Subscribe to NRx Newsletter

Aviptadil

NeuroRx and Relief Therapeutics announce enrollment of 150 patients in phase 2b/3 trial of RLF-100™ for Critical COVID-19 with Respiratory Failure

Observations of rapid recovery noted in chest x-ray and no drug-related Serious Adverse Events reported CISON PR Newswire RADNOR, Pa. and GENEVA, Nov. 13, 2020 /PRNewswire/ — NeuroRx, Inc. and Relief Therapeutics Holdings AG (SIX:RLF,OTCBB:RLFTF) (“Relief”) announced that as of today, 150 patients (out of a targeted enrollment of 165) have been enrolled in the ongoing phase 2b/3 trial of RLF-100™ […]

NeuroRx and Relief Therapeutics announce continuation of RLF-100™ trial for treatment of COVID-19 Respiratory Failure: Trial is on track to complete enrollment in 2020

CISON PR Newswire RADNOR, Pa. and GENEVA, Nov. 5, 2020 /PRNewswire/ — NeuroRx, Inc. and Relief Therapeutics Holdings AG (SIX:RLF,OTCBB:RLFTF) (“Relief”) announced that the independent Data Monitoring Committee (DMC) met yesterday and voted unanimously that NCT 04311697 should continue as planned to its full enrollment of 165 patients.  Specifically, the committee identified no safety concerns and viewed the study as capable […]

NeuroRx and Relief announce topline efficacy data from patients treated with RLF-100™ (aviptadil) under the U.S. FDA Expanded Access Protocol authorization for respiratory failure related to critical COVID-19

CISON PR Newswire – RLF-100™ therapy associated with a 9-fold increased probability of survival and recovery from respiratory failure in an open-label, prospective study– Top-line data from randomized, placebo-controlled Phase 2b/3 trial expected this quarter GENEVA and RADNOR, Pa., Oct. 13, 2020 /PRNewswire/ — RELIEF THERAPEUTICS Holding AG (SIX: RLF,OTCQB: RLFTF) and NeuroRx, Inc., today announced topline results from 45 […]

NeuroRx submits request for Emergency Use Authorization for RLF-100™ (aviptadil) in the treatment of patients with Critical COVID-19 and Respiratory Failure who have exhausted approved therapy

CISON PR Newswire Emergency Use Authorization request targets the same population as is currently permitted under FDA Expanded Access Protocol RADNOR, Pa., Sept. 23, 2020 /PRNewswire/ — NeuroRx, Inc. has submitted a request for an Emergency Use Authorization (EUA) with the US FDA for the use of RLF-100™ aviptadil in patients who are receiving intensive care […]

RLF-100 (aviptadil) clinical trial showed rapid recovery from respiratory failure and inhibition of coronavirus replication in human lung cells

CISION PR Newswire – Rapid recovery of patients on ventilators and ECMO (extracorporeal membrane oxygenation) was seen in patients with severe medical comorbidities after three days of treatment with RLF-100 under FDA Emergency Use IND authorization at multiple clinical sites – Aviptadil is being developed as the first COVID therapeutic to block replication of the […]